Rel­ma­da to ex­plore psy­che­del­ic av­enue in pur­suit of de­pres­sion treat­ment; Ital­ian man­u­fac­tur­er joins NYSE

There has been a surge in in­vest­ment in psy­che­del­ic biotechs in re­cent years, and Rel­ma­da Ther­a­peu­tics is hop­ping on board.

CNS-fo­cused Rel­ma­da will pay a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER